Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Teacher spread

0.285 · how far apart the two teachers sit on this one work

Validation status

score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

OBJECTIVE: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). DESIGN: Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker and clinical pathology data. SETTING: General community-based, prospective, longitudinal study of aging. PARTICIPANTS: A total of 754 healthy individuals serving as controls and 207 participants with AD from the Australian Imaging Biomarker and Lifestyle study (AIBL) cohort with identified biomarkers that were validated in 58 healthy controls and 112 individuals with AD from the Alzheimer Disease Neuroimaging Initiative (ADNI) cohort. RESULTS: A biomarker panel was identified that included markers significantly increased (cortisol, pancreatic polypeptide, insulinlike growth factor binding protein 2, β(2) microglobulin, vascular cell adhesion molecule 1, carcinoembryonic antigen, matrix metalloprotein 2, CD40, macrophage inflammatory protein 1α, superoxide dismutase, and homocysteine) and decreased (apolipoprotein E, epidermal growth factor receptor, hemoglobin, calcium, zinc, interleukin 17, and albumin) in AD. Cross-validated accuracy measures from the AIBL cohort reached a mean (SD) of 85% (3.0%) for sensitivity and specificity and 93% (3.0) for the area under the receiver operating characteristic curve. A second validation using the ADNI cohort attained accuracy measures of 80% (3.0%) for sensitivity and specificity and 85% (3.0) for area under the receiver operating characteristic curve. CONCLUSIONS: This study identified a panel of plasma biomarkers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity. Cross-validation within the AIBL cohort and further validation within the ADNI cohort provides strong evidence that the identified biomarkers are important for AD diagnosis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue

Archives of Neurology

Topic

Dementia and Cognitive Impairment Research

Field

Medicine

Canadian institutions

—

Funders

University of California, San DiegoNational Institute of Biomedical Imaging and BioengineeringCanadian Institutes of Health ResearchUniversity of California, Los AngelesGenentechNational Institutes of HealthServierEisaiNorthern California Institute for Research and EducationAlzheimer's AssociationAmorfix Life SciencesSynarcF. Hoffmann-La RocheEdith Cowan UniversityMedpaceBioClinicaPfizerBiogenDementia Collaborative Research Centres, AustraliaBristol-Myers SquibbEli Lilly and CompanyNational Health and Medical Research CouncilAstraZenecaNovartis Pharmaceuticals CorporationBayer HealthCareMedical Research CouncilMeso Scale DiagnosticsNational Institute on AgingCommonwealth Scientific and Industrial Research OrganisationAbbott LaboratoriesScience and Industry Endowment FundFoundation for the National Institutes of Health

Keywords

BiomarkerCohortMedicineInternal medicineProspective cohort studyOncologyReceiver operating characteristicArea under the curveGastroenterologyPathologyBiology

Has abstract in OpenAlex

yes

API

/api/v1/works/W2096321911